APLS Apellis Pharmaceuticals Inc.

26.48
+0.1  (+0%)
Previous Close 26.38
Open 26.27
Price To Book 10.59
Market Cap 1,686,657,290
Shares 63,695,517
Volume 1,101,915
Short Ratio
Av. Daily Volume 578,236
Stock charts supplied by TradingView

NewsSee all news

  1. Apellis to Present Data on APL-2 in Complement 3 Glomerulopathy at ASN Kidney Week 2019

    Company also provides an update on plans in nephrology CRESTWOOD, Ky. and WALTHAM Mass., Oct. 11, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused

  2. Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CRESTWOOD, Ky. and WALTHAM Mass., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to

  3. Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CRESTWOOD, Ky., and WALTHAM Mass., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (NASDAQ:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to

  4. Apellis Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

    CRESTWOOD, Ky. and WALTHAM, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (NASDAQ:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to

  5. Phase 2 Study Published in Ophthalmology Highlights Efficacy and Safety Data of Intravitreal APL-2 for Geographic Atrophy Secondary to Age-Related Macular Degeneration

    CRESTWOOD, Ky., and WALTHAM Mass., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (NASDAQ:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial to be initiated in early 2020.
APL-2 subcutaneous
Cold agglutinin disease (CAD)
Phase 1b trial ongoing.
APL-2 PHAROAH
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 3 enrolment to be completed 1Q 2020.
APL-2 OAKS
Geographic atrophy (GA) associated with age-related macular degeneration (AMD)
Phase 3 data due December 2019.
APL-2 subcutaneous PEGASUS
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 1b update due at ASH December 2, 2018 noted normalization of mean hemoglobin to 12.2 g/dL by day 85, an increase of 4.2 g/dL from baseline.
APL-2 PADDOCK
Paroxysmal Nocturnal Hemoglobinuria
Phase 2 initial data due at ASN November 8, 2019 at 10am ET.
APL-2 subcutaneous
Complement-dependent Nephropathies (CDN)
Phase 3 commencement of dosing announced September 3, 2019.
APL-2 PRINCE
Paroxysmal Nocturnal Hemoglobinuria (PNH)

Latest News

  1. Apellis to Present Data on APL-2 in Complement 3 Glomerulopathy at ASN Kidney Week 2019

    Company also provides an update on plans in nephrology CRESTWOOD, Ky. and WALTHAM Mass., Oct. 11, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused

  2. Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CRESTWOOD, Ky. and WALTHAM Mass., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to

  3. Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CRESTWOOD, Ky., and WALTHAM Mass., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (NASDAQ:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to

  4. Apellis Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

    CRESTWOOD, Ky. and WALTHAM, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (NASDAQ:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to

  5. Phase 2 Study Published in Ophthalmology Highlights Efficacy and Safety Data of Intravitreal APL-2 for Geographic Atrophy Secondary to Age-Related Macular Degeneration

    CRESTWOOD, Ky., and WALTHAM Mass., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (NASDAQ:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to

  6. Apellis Pharmaceuticals Announces Closing of Offering of Convertible Senior Notes

    CRESTWOOD, Ky. and WALTHAM, Mass., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to

  7. Apellis Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes

    CRESTWOOD, Ky., and WALTHAM, Mass., Sept. 12, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds

  8. Apellis Pharmaceuticals Announces Proposed Private Offering of $200 Million of Convertible Senior Notes

    CRESTWOOD, Ky., and WALTHAM, Mass., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds

  9. Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CRESTWOOD, Ky., and WALTHAM Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (NASDAQ:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to

  10. Apellis Dosed First Patient in Phase 3 Study of APL-2 for Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria

    CRESTWOOD, Ky. and WALTHAM, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (NASDAQ:APLS) announced today the dosing of the first patient in the Phase 3 clinical study PRINCE (APL2-308),

  11. Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CRESTWOOD, Ky., and WALTHAM Mass, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (NASDAQ:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to

  12. Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

    CRESTWOOD, Ky. and WALTHAM Mass., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (NASDAQ:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to